Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations

Annals of Medicine

Volumn 46, Issue 3, 2014, Pages 114-122

  Rajala, Hanna L M ^a   Porkka, Kimmo ^a   MacIejewski, Jaroslaw P ^b   Loughran Jr , Thomas P ^c   Mustjoki, Satu ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Leukemia; LGL; Lymphocyte; Oncogene; STAT3; STAT5b; Transcription factor

Indexed keywords

BP 1 102; CYCLOPHOSPHAMIDE; CYCLOSPORIN; JANUS KINASE INHIBITOR; METHOTREXATE; MOLECULAR MARKER; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; OLIGONUCLEOTIDE; OPB 3112; PHOSPHOTYROSINE; PIMOZIDE; PROTEIN INHIBITOR; PROTEIN SH2; RUXOLITINIB; STA 21; STAT3 PROTEIN; STAT5B PROTEIN; UNCLASSIFIED DRUG; STAT3 PROTEIN, HUMAN; STAT5 PROTEIN; STAT5B PROTEIN, HUMAN;

ANEMIA; AUTOIMMUNE DISEASE; CLINICAL FEATURE; DIMERIZATION; DRUG TARGETING; GAIN OF FUNCTION MUTATION; GENE MUTATION; HUMAN; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; APLASTIC ANEMIA; GENETICS; LYMPHOCYTE; METABOLISM; MUTATION; MYELODYSPLASTIC SYNDROME;

ANEMIA, APLASTIC; ANIMALS; HUMANS; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; LYMPHOCYTES; MUTATION; MYELODYSPLASTIC SYNDROMES; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR;

EID: 84899842603     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.882105     Document Type: Review

References (94)

1. Loughran TP Jr, Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteche C, et al. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med. 1985; 102: 169-75.
2. Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood. 2011; 117: 2764-74.
3. Mohan SR, Maciejewski JP. Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia. Curr Opin Hematol. 2009; 16: 27-34.
4. Zhang J, Xu X, Liu Y. A ctivation-induced cell death in T cells and autoimmunity. Cell Mol Immunol. 2004; 1: 186-92.
5. Epling-Burnette P K, Liu J H, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001; 107: 351-62.
6. Yang J, Epling-Burnette PK, Painter JS, Zou J, Bai F, Wei S, et al. Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood. 2008; 111: 1610-16.
7. Leblanc F, Zhang D, Liu X, Loughran TP. Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. Future Oncol. 2012; 8: 787-801.
8. Zhang R, Shah MV, Yang J, Nyland SB, Liu X, Yun JK, et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci USA. 2008; 105: 16308-13.
9. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012; 366: 1905-13.
10. Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012; 120: 3048-57.
11. Lim CP, Cao X. Structure, function, and regulation of STAT proteins. Mol Biosyst. 2006; 2: 536-50.
12. Maritano D, Sugrue ML, Tininini S, Dewilde S, Strobl B, Fu X, et al. The STAT3 isoforms alpha and beta have unique and specifi c functions. Nat Immunol. 2004; 5: 401-9.
13. Ambrosio R, Fimiani G, Monfregola J, Sanzari E, De Felice N, Salerno MC, et al. The structure of human STAT5A and B genes reveals two regions of nearly identical sequence and an alternative tissue specifi c STAT5B promoter. Gene. 2002; 285: 311-18.
14. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998; 334(Pt 2): 297-314.
15. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, diff erentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000; 19: 2548-56.
16. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000; 19: 2468-73.
17. Yu H, Pardoll D, Jove R. STATs in cancer infl ammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9: 798-809.
18. Wen Z, Darnell JE Jr. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no infl uence on DNA binding of Stat1 and Stat3. Nucleic Acids Res. 1997; 25: 2062-7.
19. Kang K, Robinson GW, Hennighausen L. Comprehensive meta-analysis of Signal Transducers and Activators of Transcription (STAT) genomic binding patterns discerns cell-specifi c cis-regulatory modules. BMC Genomics. 2013; 14: 4.
20. Greenhalgh CJ, Hilton DJ. Negative regulation of cytokine signaling. J Leukoc Biol. 2001; 70: 348-56.
21. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA. 1997; 94: 3801-4.
22. Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specifi c Stat3-defi cient mice. J Immunol. 1998; 161: 4652-60.
23. Akaishi H, Takeda K, Kaisho T, Shineha R, Satomi S, Takeda J, et al. Defective IL-2-mediated IL-2 receptor alpha chain expression in Stat3-defi cient T lymphocytes. Int Immunol. 1998; 10: 1747-51.
24. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007; 357: 1608-19.
25. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007; 448: 1058-62.
26. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004; 4: 97-105.
27. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene. 2000; 19: 2489-95.
28. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro. J Clin Invest. 1998; 102: 1385-92.
29. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10: 105-15.
30. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001; 20: 2499-513.
31. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002; 8: 945-54.
32. Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood. 2001; 98: 762-70.
33. Agrawal N, Frederick M J, Pickering C R, Bettegowda C, Chang K, Li R J, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011; 333: 1154-7.
34. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471: 467-72.
35. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell. 1999; 98: 295-303.
36. Harris T J, Grosso J F, Yen H R, Xin H, Kortylewski M, Albesiano E, et al. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol. 2007; 179: 4313-17.
37. Gaston JS. Cytokines in arthritis-the ' big numbers' move centre stage. Rheumatology (Oxford). 2008; 47: 8-12.
38. Fitch E, Harper E, Skorcheva I, Kurtz S E, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th 17 cytokines. Curr Rheumatol Rep. 2007; 9: 461-7.
39. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system infl ammation. Nat Med. 2007; 13: 1173-5.
40. Schmechel S, Konrad A, Diegelmann J, Glas J, Wetzke M, Paschos E, et al. Linking genetic susceptibility to Crohn ' s disease with Th 17 cell function: IL-22 serum levels are increased in Crohn ' s disease and correlate with disease activity and IL23R genotype status. Infl amm Bowel Dis. 2008; 14: 204-12.
41. Fasan A, Kern W, Grossmann V, Haferlach C, Haferlach T, Schnittger S. STAT3 mutations are highly specifi c for large granular lymphocytic leukemia. Leukemia. 2013; 27: 1598-600.
42. Ohgami RS, Ma L, Merker JD, Martinez B, Zehnder JL, Arber DA. STAT3 mutations are frequent in CD30 T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia. 2013; 27: 2244-7.
43. Rajala HL, Eldfors S, Kuusanmaki H, Andersson EI, van Adrichem AJ, Lagstrom S, et al. Deep sequencing reveals small subclones of STAT3 mutations in large granular lymphocytic leukemia. European Hematology Association, 18th Congress of EHA, June 13-16, 2013, Stockholm, Sweden.
44. Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V, et al. Somatic mutations activating STAT3 in human infl ammatory hepatocellular adenomas. J Exp Med. 2011; 208: 1359-66.
45. Couronne L, Scourzic L, Pilati C, Valle VD, Duffourd Y, Solary E, et al. STAT3 mutations identifi ed in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica. 2013; 98: 1748-52.
46. Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, et al. Frequent in-frame somatic deletions activate gp130 in infl ammatory hepatocellular tumours. Nature. 2009; 457: 200-4.
47. Hu G, Witzig TE, Gupta M. A novel missense (M206K) STAT3 mutation in diff use large B cell lymphoma deregulates STAT3 signaling. PLoS One. 2013; 8: e67851.
48. Kim MS, Lee SH, Yoo NJ, Lee SH. STAT3 exon 21 mutation is rare in common human cancers. Acta Oncol. 2013; 52: 1221-2.
49. Young N S. Acquired aplastic anemia. Ann Intern Med. 2 002; 1 36: 534-46.
50. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009; 361: 1872-85.
51. Karadimitris A, Li K, Notaro R, Araten DJ, Nafa K, Thertulien R, et al. Association of clonal T-cell large granular lymphocyte disease and paroxysmal nocturnal haemoglobinuria (PNH): further evidence for a pathogenetic link between T cells, aplastic anaemia and PNH. Br J Haematol. 2001; 115: 1010-14.
52. Jerez A, Clemente MJ, Makishima H, Rajala H, Gomez-Segui I, Olson T, et al. STAT3-mutations indicate the presence of subclinical T cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013; 122: 2453-9.
53. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA. 1997; 94: 7239-44.
54. Imada K, Bloom ET, Nakajima H, Horvath-Arcidiacono JA, Udy GB, Davey HW, et al. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med. 1998; 188: 2067-74.
55. Eckelhart E, Warsch W, Zebedin E, Simma O, Stoiber D, Kolbe T, et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood. 2011; 117: 1565-73.
56. Hwa V, Camacho-Hubner C, Little BM, David A, Metherell LA, El-Khatib N, et al. Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene. Horm Res. 2007; 68: 218-24.
57. Kanai T, Jenks J, Nadeau KC. The STAT5b pathway defect and autoimmunity . Front Immunol. 2012; 3: 234.
58. Yao Z, Cui Y, Watford WT, Bream JH, Yamaoka K, Hissong BD, et al. Stat5a/b are essential for normal lymphoid development and diff erentiation . Proc Natl Acad Sci USA. 2006; 103: 1000-5.
59. Fabbro D. BCR-ABL signaling: a new STATus in CML. Nat Chem Biol. 2012; 8: 228-9.
60. Rajala H L, Mustjoki S. S TAT5b in LGL leukemia-a novel therapeutic target? Oncotarget. 2013; 4: 808-9.
61. Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood. 2000; 96: 2269-76.
62. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996; 13: 247-54.
63. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011; 117: 3421-9.
64. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofi brosis. Cancer Cell. 2005; 7: 387-97.
65. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013; 32: 2601-13.
66. Funakoshi-Tago M, Tago K, Abe M, Sonoda Y, Kasahara T. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. J Biol Chem. 2010; 285: 5296-307.
67. Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, McMahon M, et al. Identifi cation and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol. 1998; 18: 3871-9.
68. Ariyoshi K, Nosaka T, Yamada K, Onishi M, Oka Y, Miyajima A, et al. Constitutive activation of STAT5 by a point mutation in the SH2 domain. J Biol Chem. 2000; 275: 24407-13.
69. Yamada K, Ariyoshi K, Onishi M, Miyajima A, Hayakawa F, Towatari M, et al. Constitutively active STAT5A and STAT5B in vitro and in vivo: mutation of STAT5 is not a frequent cause of leukemogenesis. Int J Hematol. 2000; 71: 46-54.
70. Rajala HL, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstrom S, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013; 121: 4541-50.
71. Andersson EI, Rajala HL, Eldfors S, Ellonen P, Olson T, Jerez A, et al. Novel somatic mutations in large granular lymphocytic leukemia aff ecting the STAT-pathway and T-cell activation. Blood Cancer J. 2013; 3: e168.
72. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19.
73. Saha A, Robertson ES. Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. Clin Cancer Res. 2011; 17: 3056-63.
74. Hart DN, Baker BW, Inglis MJ, Nimmo JC, Starling GC, Deacon E, et al. Epstein-Barr viral DNA in acute large granular lymphocyte (natural killer) leukemic cells. Blood. 1992; 79: 2116-23.
75. Coppo P, Gouilleux-Gruart V, Huang Y, Bouhlal H, Bouamar H, Bouchet S, et al. STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma. Leukemia. 2009; 23: 1667-78.
76. Shukla S, Shishodia G, Mahata S, Hedau S, Pandey A, Bhambhani S, et al. Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection . Mol Cancer. 2010; 9: 282.
77. Thomas A, Perzova R, Abbott L, Benz P, Poiesz MJ, Dube S, et al. LGL leukemia and HTLV. AIDS Res Hum Retroviruses. 2010; 26: 33-40.
78. O' Keefe CL, Plasilova M, Wlodarski M, Risitano AM, Rodriguez AR, Howe E, et al. Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses. J Immunol. 2004; 172: 1960-9.
79. Rajala HL, Eldfors S, Kuusanmaki H, Andersson EI, van Adrichem AJ, Lagstrom S, et al. Discovery of STAT5b mutations and small subclones of STAT3 mutations in large granular lymphocytic (LGL) leukemia. Blood (ASH Annual Meeting Abstracts). 2012; 120(Abstract 871).
80. Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomaLinstability and DNA hypermethylation . Cancer Cell. 2012; 22: 645-55.
81. Ohkawa T, Seki S, Dobashi H, Koike Y, Habu Y, Ami K, et al. Systematic characterization of human CD8 T cells with natural killer cell markers in comparison with natural killer cells and normal CD8 T cells. Immunology. 2001; 103: 281-90.
82. Langerak AW, Groenen PJ, Bruggemann M, Beldjord K, Bellan C, Bonello L, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations . Leukemia. 2012; 26: 2159-71.
83. Langerak AW, van Den Beemd R, Wolvers-Tettero IL, Boor PP, van Lochem EG, Hooijkaas H, et al. Molecular and fl ow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood. 2001; 98: 165-73.
84. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010; 116: 772-82.
85. Gillespie GM, Wills MR, Appay V, O' Callaghan C, Murphy M, Smith N, et al. Functional heterogeneity and high frequencies of cytomegalovirus-specifi c CD8 T lymphocytes in healthy seropositive donors. J Virol. 2000; 74: 8140-50.
86. Mustjoki S, Ekblom M, Arstila T P, DybedaLi, Epling-Burnette P K, Guilhot F, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009; 23: 1398-405.
87. Posnett D N, Sinha R, Kabak S, Russo C. Clonal populations of T cells in normal elderly humans: the T cell equivalent to " benign monoclonal gammapathy ". J Exp Med. 1994; 179: 609-18.
88. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenograft s. Proc Natl Acad Sci USA. 2012; 109: 9623-8.
89. Hayakawa F, Sugimoto K, Kurahashi S, Sumida T, Naoe T. A novel STAT3 inhibitor OPB-31121 induces tumor-specifi c growth inhibition in a wide range of hematopoietic malignancies without growtHsuppression of normal hematopoietic cells. Blood (ASH Annual Meeting Abstracts). 2011; 118(Abstract 577).
90. Souissi I, Najjar I, Ah-Koon L, Schischmanoff PO, Lesage D, Le Coquil S, et al. A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-kappaB. BMC Cell Biol. 2011; 12:14.
91. Page BD, Khoury H, Laister RC, Fletcher S, Vellozo M, Manzoli A, et al. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J Med Chem. 2012; 55: 1047-55.
92. Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov. 2013; 12: 611-29.
93. Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, et al. The STAT5 inhibitor pimozide displays effi cacy in models of acute myelogenous leukemia driven by FLT3 mutations. Genes Cancer. 2012; 3: 503-11.
94. Epling-Burnette PK, Catlett-Falcone R, Kothapalli R, Oshiro M, Jove R, Loughran TP. Induction of apoptosis in large granular lymphocyte (Lgl) leukemia by jak tyrosine kinase inhibitor AG-490: role of STAT3-regulated MCL-1. ISEH Annual Meeting: Experimental Hematology. 2000; 28: 90-1.